Research Overview: Levocetirizine Investigation
Levocetirizine is a third-generation antihistamine compound, representing the R-enantiomer of cetirizine, extensively investigated in cellular inflammation and allergic response research. This pharmaceutical-grade specimen from Cipla provides researchers with a standardised preparation for studying histamine receptor mechanisms and inflammatory cascade modulation in laboratory settings.
Laboratory studies have focused on levocetirizine’s selective H1-receptor antagonism properties, examining its pharmacokinetic profile and cellular uptake characteristics across various experimental models. The compound’s enhanced bioavailability compared to its racemic parent molecule makes it valuable for investigating antihistamine receptor binding dynamics and downstream signalling pathway interactions.
Laboratory Research Applications
Research teams investigating allergic inflammation pathways frequently utilise levocetirizine to examine histamine-mediated cellular responses in controlled laboratory environments. The compound’s selectivity for H1 receptors enables precise investigation of histaminergic signalling without significant interference from other receptor subtypes, making it ideal for mechanistic studies of inflammatory mediator release.
Comparative pharmacological research has evaluated levocetirizine alongside other antihistamine compounds available through our comprehensive Stroid UK Shop, examining relative binding affinities and duration of receptor occupancy. Studies have also investigated its potential interactions with other research compounds, including those available in our SARMs collection and peptide research compounds.
Cellular metabolism research has examined levocetirizine’s hepatic processing pathways, investigating cytochrome enzyme interactions and metabolite formation patterns. These studies contribute to broader understanding of drug metabolism mechanisms and provide valuable data for pharmaceutical development research protocols.
Technical Specifications
| Parameter | Value |
|---|---|
| Active Compound | Levocetirizine Dihydrochloride |
| Strength | 5 mg per unit |
| Manufacturer | Cipla Limited |
| CAS Number | 130018-87-0 |
| Molecular Formula | C₂₁H₂₇Cl₃N₂O₃ |
| Molecular Weight | 461.81 g/mol |
| Storage Requirements | Room temperature, dry environment |
Our levocetirizine research category contains additional compounds for comparative antihistamine studies, enabling comprehensive investigation protocols across multiple experimental parameters.
Research Compliance Statement
This levocetirizine preparation is supplied exclusively for in-vitro laboratory research applications and controlled experimental studies. This compound is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must ensure appropriate laboratory safety protocols are implemented when handling this material, including proper ventilation, personal protective equipment, and waste disposal procedures. All research activities must comply with relevant institutional guidelines and regulatory requirements for laboratory chemical handling and experimental research protocols.
